Identify factors that account for individual differences in pathobiology and in responses to treatments
Objective 4: Identify factors that account for individual differences in pathobiology and in responses to treatments
Research advances in areas such as genomics and other “omics” (e.g., proteomics, metabolomics) have provided new opportunities to deepen our understanding of heart, lung, blood, and sleep (HLBS) pathobiological processes and how these vary among individual patients. Accelerating progress toward precise, individualized prevention efforts and medical interventions will require research into biological factors, environmental exposures, and other influences that account for differences in pathobiology and unique responses to treatment (including drug reactions and other adverse events). This research will allow personal and clinical decisions, practices, and medical products to be tailored to the individual patient to help optimize outcomes.
Envision a future in which we are able to...
Develop precise clinical interventions based on individual environmental exposures, behaviors, genotypes, and molecular-cellular phenotypes.
Accelerate the incorporation of new imaging, omics, and sensor technologies with advanced data analytics to inform more precise clinical classification of chronic diseases (e.g., asthma, pulmonary fibrosis, chronic obstructive lung disease, heart failure) and thereby enable more accurate diagnosis and treatment.
Which phenotypic, biomarker, and molecular characteristics predict outcome and, when applied in clinical studies, predict differential responses to therapy in individuals and in different populations with HLBS diseases? (4.CQ.01)
What factors render individuals or populations subjected to the same exposures (e.g., diet, smoking, other environmental and social exposures) resilient or susceptible to disease? (4.CQ.02)
What underlies secondary resilience, such that some people are protected from the complications of HLBS diseases? (4.CQ.03)
Which patients benefit from rehabilitation treatments (e.g., cardiac, vascular, and pulmonary), and how can the benefits of rehabilitation treatments be sustained long term? (4.CQ.04)
How does the pathobiology that underlies nonobstructive ischemic heart disease and the associated risks for acute coronary syndrome and early mortality differ between subpopulations, and what are the targets for treatment and prevention? (4.CQ.05)